ECSP10010175A - Productos quimioterapéuticos cristalinos - Google Patents

Productos quimioterapéuticos cristalinos

Info

Publication number
ECSP10010175A
ECSP10010175A EC2010010175A ECSP10010175A ECSP10010175A EC SP10010175 A ECSP10010175 A EC SP10010175A EC 2010010175 A EC2010010175 A EC 2010010175A EC SP10010175 A ECSP10010175 A EC SP10010175A EC SP10010175 A ECSP10010175 A EC SP10010175A
Authority
EC
Ecuador
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
indazol
Prior art date
Application number
EC2010010175A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP10010175A publication Critical patent/ECSP10010175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma cristalina 2 de N-(4-(3-amino-1H-indazol-4-il)fenil)-N´-(2-fluoro-5-metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento para pacientes que padecen una enfermedad para usarla.
EC2010010175A 2007-10-19 2010-05-14 Productos quimioterapéuticos cristalinos ECSP10010175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010175A true ECSP10010175A (es) 2010-06-29

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010175A ECSP10010175A (es) 2007-10-19 2010-05-14 Productos quimioterapéuticos cristalinos

Country Status (19)

Country Link
US (1) US7772404B2 (es)
EP (1) EP2195299A1 (es)
JP (1) JP2011500708A (es)
KR (1) KR20100084665A (es)
CN (1) CN101827825B (es)
AU (1) AU2008312534A1 (es)
BR (1) BRPI0818337A2 (es)
CA (1) CA2699356A1 (es)
CO (1) CO6270221A2 (es)
CR (1) CR11444A (es)
DO (1) DOP2010000111A (es)
EC (1) ECSP10010175A (es)
GT (1) GT201000099A (es)
MX (1) MX2010004287A (es)
PA (1) PA8800401A1 (es)
RU (1) RU2010119920A (es)
UA (1) UA99490C2 (es)
WO (1) WO2009052231A1 (es)
ZA (1) ZA201002094B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CN101827825B (zh) 2012-11-21
CA2699356A1 (en) 2009-04-23
CO6270221A2 (es) 2011-04-20
MX2010004287A (es) 2010-04-30
UA99490C2 (en) 2012-08-27
ZA201002094B (en) 2011-11-30
GT201000099A (es) 2012-03-26
PA8800401A1 (es) 2009-05-15
EP2195299A1 (en) 2010-06-16
AU2008312534A1 (en) 2009-04-23
WO2009052231A1 (en) 2009-04-23
CN101827825A (zh) 2010-09-08
KR20100084665A (ko) 2010-07-27
RU2010119920A (ru) 2011-11-27
US7772404B2 (en) 2010-08-10
DOP2010000111A (es) 2010-07-15
US20090124816A1 (en) 2009-05-14
BRPI0818337A2 (pt) 2017-05-23
JP2011500708A (ja) 2011-01-06
CR11444A (es) 2010-10-05

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CL2010001362A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras.
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
ECSP10010176A (es) Productos quimioterapéuticos cristalinos
ECSP10010175A (es) Productos quimioterapéuticos cristalinos
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
CL2008003709A1 (es) Uso de 4-[2-(4-metilfenil-sulfanil)fenil]piperidina y sus sales, para tratar una enfermedad seleccionada de retardo psicomotriz, depresion grave, ansiedad, enfermedad de parkinson, epilepsia, entre otras.
CR11386A (es) Productos quimioterapeuticos cristalinos
UY31407A1 (es) "productos quimioterapéuticos cristalinos"
IS2712B (is) Notkun týrósínkínasatálma til að meðhöndla sykursýki
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.
UY31988A (es) Compuestos de pirimidinilsulfonamida para utilizar en el tratamiento de una enfermedad mediada por quimiocina
CR7755A (es) Thiazolibifenilamidas